Current report
Open the filing on sec.gov
Tempest Therapeutics, Inc. (TPST)
Nasdaq: TPST · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
The companyfiscal 2017, as filed
Revenue$295,000-54.8%
Net income-$84.6M-2.8%
Earnings per sharen/a
Operating cash flow-$20.3M+67.1%
Cash$17.6M-60.0%
Debt$599,000
Shareholders’ equity-$131M-220.8%
Shares, dilutedn/a
Return on equity-393.8%
The recordfrom its filings
Filings in 202696
Newest filingNov 12 · 8-K
Annual reportMar 30, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$1.0M
Patents granted16
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$40.5MCash from operations -$20.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Extra proxy material
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.